NASDAQ$SGMT
Sagimet Biosciences Inc-A · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Sagimet Biosciences reported full year 2023 financial results and provided corporate updates.
Sagimet Biosciences reported positive topline data from the Phase 2b FASCINATE-2 trial and is preparing to initiate a pivotal Phase 3 trial in the second half of 2024. They completed a follow-on offering in January 2024 for $104.7 million in net proceeds, with cash, cash equivalents, and marketable securities totaling $94.9 million as of December 31, 2023.
- Positive topline data from the Phase 2b FASCINATE-2 trial was reported, with denifanstat meeting both primary efficacy endpoints and demonstrating a statistically significant reduction in fibrosis at week 52.
- A late-breaking poster was presented at AASLD showcasing the beneficial shift in lipid profile in denifanstat-treated patients.
- An End-of-Phase 2 meeting with the FDA is expected in the first half of 2024, and preparations are underway to initiate a pivotal Phase 3 trial evaluating denifanstat in MASH patients in the second half of 2024.
- The anticipated cash runway was extended through 2025 by completing a follow-on offering in January 2024 for $104.7 million in net proceeds; cash, cash equivalents, and marketable securities totaled $94.9 million as of December 31, 2023.
Headline financials
Revenue & EPS history
Sagimet Biosciences · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q4 2023
-3.0%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+17.0%
Avg return
30 days after
43%
6 / 14 earnings
Positive
+16.0%
Q4 2023
Best reaction
-21.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -0.2% | -10.2% | -16.5% | |
| Q3 2025 | -12.5% | -11.3% | -29.4% | |
| Q1 2025 | +6.6% | +7.1% | +118.6% | |
| Q4 2024 | +3.5% | -7.0% | -30.5% | |
| Q3 2024 | -21.4% | -26.7% | -27.1% | |
| Q2 2024 | +3.8% | +6.0% | +39.8% | |
| Q1 2024 | +8.4% | +8.2% | -5.5% | |
| Q1 2023 | +8.4% | +8.2% | -5.5% | |
| Q4 2023 | +16.0% | +20.2% | -7.5% | |
| Q3 2022 | -2.5% | +14.5% | +113.9% | |
| Q3 2023 | -2.5% | +14.5% | +113.9% | |
| Q2 2022 | -16.3% | -5.1% | -8.6% | |
| Q2 2023 | -16.3% | -5.1% | -8.6% | |
| Q4 2022 | -16.3% | -5.1% | -8.6% | |
| Q1 2022 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro